Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy

被引：0
作者：
Michael Dieckmeyer
Stefan Ruschke
Alexander Rohrmeier
Jan Syväri
Ingo Einspieler
Vanadin Seifert-Klauss
Monika Schmidmayr
Stephan Metz
Jan S. Kirschke
Ernst J. Rummeny
Claus Zimmer
Dimitrios C. Karampinos
Thomas Baum
机构：
[1] Technische Universität München,Department of Diagnostic and Interventional Neuroadiology, Klinikum rechts der Isar
[2] Technische Universität München,Department of Radiology, Klinikum rechts der Isar
[3] University Medical Center Regensburg,Department of Radiology
[4] Technische Universität München,Department of Gynecology and Obstetrics, Klinikum rechts der Isar
来源：
BMC Musculoskeletal Disorders | / 20卷
关键词：
Osteoporosis; Bisphosphonates; Aromatase inhibitor; Vertebral bone marrow; Proton density fat fraction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Chemical Shift-Encoded MRI of the Lumbar Vertebral Bone Marrow for Detecting Osteoporosis With Low Trabecular Bone Quality in Patients With Breast Cancer Receiving Aromatase Inhibitors
    Misaka, Tomofumi
    Hashimoto, Yukihiko
    Ashikaga, Ryuichiro
    Ishida, Takayuki
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2024, 60 (04) : 1379 - 1389
  • [22] The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women
    Mouridsen, HT
    Robert, NJ
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (12) : 1678 - 1689
  • [23] IBISII: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole
    Cuzick, Jack
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (09) : 1377 - 1385
  • [24] Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
    Chen, Shanshan
    Bo, Lan
    Lv, Dan
    Ma, Fei
    BREAST CARE, 2022, 17 (04) : 391 - 402
  • [25] Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
    Sun, Shengliang
    Wang, Fuchao
    Dou, Honglei
    Zhang, Longqiang
    Li, Jiwen
    ONCOTARGETS AND THERAPY, 2016, 9 : 6029 - 6036
  • [26] Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors
    Ogata, Nanae
    Toh, Uhi
    Sudou, Tomoya
    Ogata, Suguru
    Takao, Yuko
    Sugihara, Rie
    Watanabe, Hideaki
    Matushima, Shuntaro
    Akagi, Yoshito
    ANTICANCER RESEARCH, 2022, 42 (08) : 4139 - 4143
  • [27] Protocol for Exercise Program in Cancer and Cognition (EPICC): A randomized controlled trial of the effects of aerobic exercise on cognitive function in postmenopausal women with breast cancer receiving aromatase inhibitor therapy
    Gentry, Amanda L.
    Erickson, Kirk I.
    Sereika, Susan M.
    Casillo, Frances E.
    Crisafio, Mary E.
    Donahue, Patrick T.
    Grove, George A.
    Marsland, Anna L.
    Watt, Jennifer C.
    Bender, Catherine M.
    CONTEMPORARY CLINICAL TRIALS, 2018, 67 : 109 - 115
  • [28] Review of bone health in women receiving endocrine therapy because of breast cancer
    Kollar, Reka
    Leel-Ossy, Tamas
    Palffy, Veronika
    Dank, Magdolna
    Horvath, Csaba
    Meszaros, Szilvia
    ORVOSI HETILAP, 2024, 165 (21) : 813 - 821
  • [29] Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors
    Mincey, Betty A.
    Duh, Mei Sheng
    Thomas, Simu K.
    Moyneur, Erick
    Marynchencko, Maryna
    Boyce, Simone Peart
    Mallett, David
    Perez, Edith A.
    CLINICAL BREAST CANCER, 2006, 7 (02) : 127 - 132
  • [30] The influence of bone mineral density and bisphosphonate therapy on the determinants of oral health and changes on dental panoramic radiographs in postmenopausal women
    Grgic, Olja
    Kovacev-Zavisic, Branka
    Veljovic, Tanja
    Novakovic-Paro, Jovanka
    Maravic, Tatjana
    Bajkin, Branislav
    CLINICAL ORAL INVESTIGATIONS, 2017, 21 (01) : 151 - 157
12345